{
    "nctId": "NCT06341621",
    "briefTitle": "Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib",
    "officialTitle": "A Prospective, Randomized, Open-label, Multicenter Phase III Study to Explore Chemotherapy Omission in ER+/HER2-endocrine-sensitive Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1900,
    "primaryOutcomeMeasure": "Invasive disease free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* women aged 18-80 years old;\n* Patient has localized invasive breast carcinoma with1-3 positive lymph nodes, T1-T2\uff0cand is ER+/HER2- confirmed by histopathology after early breast cancer surgery#HER2-negative breast cancer (based on most recently analyzed biopsy) defined as a negative in situ hybridization test or an Immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (Fluorescence in situ hybridization (FISH), Chromogenic in situ hybridization (CISH) .\n* ER\u226550%\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n* Has adequate organ function meeting the following criteria: (1) adequate bone marrow function: hemoglobin \u2265 90 g/L (no blood transfusion within 14 days); absolute neutrophil count \u2265 1.5 x 109 /L; platelet count \u2265 100 \\* 109 /L; (2)adequate liver and kidney function: Alanine Aminotransferase (ALT) \u2264 3\u00d7upper limit of normal (ULN), Aspartate Aminotransferase (AST) \u2264 3\u00d7ULN, Total Bilirubin (TBIL)\u2264 1.5\u00d7ULN, serum creatinine \u2264\n\n  1\u00d7ULN#and with endogenous creatinine clearance rate of \\>50 ml/min (Cockcroft-Gault formula).\n* Participants voluntarily joined the study, has signed informed consent before any trial related activities are conducted, has good compliance and has agreed to follow-up.\n\nExclusion Criteria:\n\n* Has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy or endocrine therapy#;\n* Has bilateral breast cancer;\n* Has previous history of additional malignancy, with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ.\n* Has metastatic (Stage 4) breast cancer;\n* Has any \u2265T3 lesion\n* Is pregnant, is breast feeding women, or women of childbearing age who cannot practice effective contraceptives;\n* Patients participating in other clinical trials at the same time;\n* Has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left ventricular ejection fraction (LVEF) \\< 50% (cardiac ultrasound); severe cardio cerebral vascular disease within the 6 months previous of randomization (such as unstable angina, chronic heart failure, uncontrolled hypertension with blood pressure\\>150/90mmgh, myocardial infarction, or cerebral blood vessel); diabetic patients with poor blood glucose control; patients with severe hypertension;\n* Has severe or uncontrolled infection;\n* the researchers judged patients to be unsuitable for the study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}